Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDUN: AGA2115 in Adults with Osteogenesis Imperfecta Types I, III, or IV
2025-522951-24-00Phase 2Authorised
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing AGA2115 dose-ranging arm with Placebo arm (2 arms). Primary endpoint: Percent change from Baseline at Month 12 in lumbar spine BMD. Planned start Jun 2026; status: authorised.
02
Drugs
AGA2115
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2025-522951-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522951-24-00.